Abstract
High-dose methotrexate (MTX) is one of the agents currently used in intensive adjuvant chemotherapy regimens for nonmetastatic osteosarcoma. To elucidate the role of high-dose MTX in this disease, we present the history of trials conducted with MTX from the first single-agent studies through progressively complex combination regimens. With this background, some of the basic dissues concerning MTX therapy in osteosarcoma are discussed. [J Natl Cancer Inst 1988;80:626-656].
Original language | English (US) |
---|---|
Pages (from-to) | 626-655 |
Number of pages | 30 |
Journal | Journal of the National Cancer Institute |
Volume | 80 |
Issue number | 9 |
DOIs | |
State | Published - Jul 6 1988 |
Externally published | Yes |
ASJC Scopus subject areas
- Oncology
- Cancer Research